Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
NCT07098299Phase 1Recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in solid tumor, sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Incidence of Dose Limiting Toxicities - Metformin only stage at 14 days, Incidence of Dose Limiting Toxicities - Chemotherapy or Immunotherapy plus Metformin Stage and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07098299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098299.